Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Business Overview: BioCardia is a clinical-stage biotechnology company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Key programs include the CardiAMP autologous cell therapy for ischemic heart failure and chronic myocardial ischemia, and the CardiALLO allogeneic mesenchymal stem cell therapy. The company utilizes its Helix transendocardial biotherapeutic delivery system.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,259) | $(2,712) |
| Net Loss Per Share (Basic & Diluted) | $(0.21) | $(0.59) |
| Research & Development Expenses | $1,235 | $1,530 |
| Selling, General & Administrative Expenses | $1,031 | $1,196 |
| Cash and Cash Equivalents (End of Period) | $951 | $949 |
| Accumulated Deficit | $(170,608) | $(162,833) |
| Stockholders' Equity (Deficit) | $(1,066) | $(1,520) |
Liquidity: As of March 31, 2026, the company held $951,000 in cash and cash equivalents. Management has raised substantial doubt about the company's ability to continue as a going concern beyond June 2026 without additional funding.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $460,000 (17%) compared to Q1 2025.
- R&D: Decreased by $295,000, primarily due to the closeout of the CardiAMP Heart Failure Trial, partially offset by early enrollment in the CardiAMP Heart Failure II Trial and regulatory activities in Japan.
- SG&A: Decreased by $165,000, driven by lower professional service fees.
- Net Loss Improvement: Net loss narrowed by $453,000 year-over-year, reflecting the reduction in operating expenses.
- Capital Raise: The company raised $225,000 in gross proceeds from the sale of 184,725 shares under its At-The-Market (ATM) offering during Q1 2026, compared to $212,000 in Q1 2025.
Outlook, Risks, and Management Commentary
Regulatory and Clinical Progress
- Japan (PMDA): In February 2026, the PMDA indicated that clinical safety and efficacy evidence for CardiAMP in ischemic heart failure is likely sufficient for market clearance. The company is preparing for the formal Shonin submission (PMA application).
- United States (FDA): In May 2026, the FDA expressed no safety concerns regarding CardiAMP and confirmed that Premarket Approval (PMA) remains the appropriate pathway. The FDA recommended continuing the ongoing CardiAMP HF II trial as a confirmatory study.
- CardiAMP HF II: A Phase III confirmatory trial for patients with elevated NTproBNP levels is actively recruiting at four sites.
- Helix Delivery System: The FDA agreed that the Helix catheter could potentially be approved simultaneously with the CardiAMP cell therapy or via a DeNovo pathway.
Liquidity and Going Concern
Management explicitly states that cash on hand ($951,000) is insufficient to fund planned expenditures beyond June 2026. The company plans to raise additional capital through equity, debt, or collaboration arrangements. Failure to secure funding could force the company to reduce expenses, delay programs, or cease operations.
Listing Compliance Risk
On April 10, 2026, the company received notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement ($2.5 million) due to an equity balance of $895,000 as of December 31, 2025. The company has until May 25, 2026, to submit a plan to regain compliance. Failure to do so could result in delisting.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the stated inability to fund operations beyond June 2026.
- Nasdaq Compliance: Monitor the submission and acceptance of the plan to regain compliance with Nasdaq listing rules by the May 25, 2026 deadline.
- Regulatory Milestones: Track the status of the Shonin submission in Japan and the FDA's feedback on the CardiAMP HF II trial design.
- ATM Capacity: Note that approximately $4.5 million of common stock remains available for sale under the current ATM agreement as of May 14, 2026.
- Going Concern: Review the "Liquidity and Capital Resources" section for updates on the substantial doubt regarding the company's ability to continue as a going concern.